首页|靶向新型冠状病毒S蛋白的侵入抑制剂研究进展

靶向新型冠状病毒S蛋白的侵入抑制剂研究进展

扫码查看
由严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)引发的新型冠状病毒感染(COVID-19)给人类生命健康和社会经济发展造成了极为严重的影响。随着病毒的持续变异,现有疫苗和治疗药物效果下降,公共卫生风险仍然存在。因此,亟需开发针对新突变株的新靶点和新机制的药物。S蛋白是SARS-CoV-2重要的表面蛋白,其介导着病毒侵入宿主细胞这一关键步骤,是抗新型冠状病毒入侵的理想靶点。通过对近年来S蛋白抑制剂的研究实例进行分析,对该领域取得的进展进行总结,旨在为抗SARS-CoV-2药物的研发提供参考。
Recent Advances in Entry Inhibitors Targeting SARS-CoV-2 Spike Protein
Novel coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused extremely serious impact on human life and health as well as social and economic development.The ongoing mutation of the virus poses a significant public health risk by limiting the effectiveness of current vaccines and drugs.Therefore,there is an urgent need to discover drugs with new targets and new mechanisms to combat potential pandemics caused by mutant viruses.S protein is an important surface protein of SARS-CoV-2 that mediates the critical step of viral invasion into host cells.Spike proteins play a crucial role in viral entry and are considered attractive targets for antiviral drugs.By analyzing the research examples of S protein inhibitors in recent years,this paper summarizes the progress made in this field,aiming to provide a reference for the research and development of anti-SARS-CoV-2 drugs.

SARS-CoV-2antiviral drugSpike proteininhibitordrug resistance

高恒、胡立德、张继伟、贾惠婻、展鹏、刘新泳

展开 >

山东大学药学院药物化学研究所化学生物学教育部重点实验室,山东济南 250012

严重急性呼吸系统综合征冠状病毒2型 抗病毒药物 S蛋白 抑制剂 耐药

国家重点研发计划山东省实验室项目

2023YFC2606500SYS202205

2024

药学进展
中国药科大学

药学进展

影响因子:0.624
ISSN:1001-5094
年,卷(期):2024.48(5)
  • 67